Current Use of Nephelometric Quantification of Serum Free Light Chains (FLCs) in the Management of Plasma Cell Dyscrasias, and the Potential Benefits of Point-Of-Care Testing.
TypeMeetings and Proceedings
MetadataShow full item record
Quantitative nephelometric assays detecting polyclonal sheep anti-sera and serum FLCs (e.g. Freelite®) are the gold standard method for monitoring FLC secretion from myeloma cells, but are only available in central laboratories. The frequent delay between venepuncture and assay results can affect diagnosis, treatment decisions and patient communication. Second generation point-of-care assays have been developed using monoclonal antibodies to FLCs, producing results in 10 minutes (e.g. Seralite®). This study investigates potential impact on care of patients with plasma cell dyscrasias.